| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Payments under finance lease obligations | 56 | 24 |
| Net cash (used in) provided by financing activities | -24,006 | -6,245 |
| Decrease in cash, cash equivalents and restricted cash | -51,359 | -30,778 |
| Cash and cash equivalents at beginning of period | 108,228 | - |
| Cash and cash equivalents at end of period | 56,869 | - |
Mersana Therapeutics, Inc. (MRSN)
Mersana Therapeutics, Inc. (MRSN)